Drug Trial Radar · NCT03470441
A Study of Acute Myocardial Infarction Using FDY-5301
Last checked: Nov 19, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
Oct 27, 2017
Primary completion
Jul 14, 2018
Study completion Jan 3, 2019
Sponsor
- Lead sponsor
- Faraday Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 20, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics (PK) of three dose levels of FDY-5301 compared to placebo in STEMI patients undergoing PCI.
Conditions
- Acute Myocardial Infarction
- STEMI
Interventions
FDY-5301Drug
FDY-5301 will be administered once, intravenously, by a healthcare professional. Dosage will be administered on a body weight basis, according to treatment assignment and using the subject's body weight determined on the dose administration day.
PlaceboOther
Placebo will be administered intravenously by a healthcare professional. Dosage will be administered on a body weight basis, according to treatment assignment and using the subject's body weight determined on the dose administration day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Arrhythmias of Interest, 48 Hours (Overall)Time frame: First 48 hours post-treatment
- Arrhythmias of Interest Incidence Rate, 48 Hours (Overall)Time frame: 48 hours post-treatment
- Arrhythmias of Interest, 14 Days (Overall)Time frame: 48 hours to 14 days Post Percutaneous Coronary Intervention (PCI)
- Arrhythmias of Interest Incidence Rate, 14 Days (Overall)Time frame: 48 hours to 14 days Post Percutaneous Coronary Intervention (PCI)
Locations
23 sites in 4 countries. Site status is shown where the registry gives one.
Minneapolis Heart Institute
Minneapolis, Minnesota
Montefiore Medical Center
The Bronx, New York
Budai Irgalmasrendi Kórház
Budapest, Hungary
Magyar Honvédség Egészségügyi Központ
Budapest, Hungary
Debreceni Egyetem Klinikai Központ, Kardiológiai és Szívsebészeti Klinika
Debrecen, Hungary
Borsod-Abaúj-Zemplén Megyei Központi Kórház
Miskolc, Hungary
Zala Megyei Szent Rafael Kórház
Zalaegerszeg, Hungary
Samodzielny Publiczny Specjalistyczny Szpital Zachodnii im. Jana Pawła II, Oddział Kardiologii Inwazyjnej
Grodzisk Mazowiecki, Poland
Samodzielny Publiczny Specjalistyczny Szpital Zachodnii im. Jana Pawła II, Oddział Kardiologii Inwazyjnej
Krakow, Poland
Klinika Elektrokardiologii; Centralny Szpital Kliniczny Uniwersytetu Medycznego w Łodzi
Lodz, Poland
Miedziowe Centrum Zdrowia
Lubin, Poland
Klinika Kardiologii Inwazyjnej; Centralny Szpital Kliniczny MSWiA w Warszawie
Warsaw, Poland
KLINIKA KARDIOLOGII, 4 Wojskowy Szpital Kliniczny
Wroclaw, Poland
Samodzielny Publiczny Szpital Kliniczny Nr 7 Śląskiego Uniwersytetu Medycznego w Katowicach, Górnośląskie Centrum Medyczne im. Prof. Leszka Kieca., III Oddz. Kardiologii
Katowice, Silesian Voivodeship, Poland
Ninewells Hospital and Medical School
Dundee, United Kingdom
Royal Infirmary of Edinburgh
Edinburgh, United Kingdom
Golden Jubilee National Hospital
Glasgow, United Kingdom
Royal Devon and Exeter Hospital Cardiology Department
Exeter, Devon, United Kingdom
Wythenshawe Hospital
Manchester, Greater Manchester, United Kingdom
Glenfield Hospital
Leicester, Leicestershire, United Kingdom
University of Oxford
Oxford, Oxfordshire, United Kingdom
Freeman Hospital
Newcastle upon Tyne, Tyne and Wear, United Kingdom
New Cross Hospital
Wolverhampton, West Midlands, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.